Neogen Corporation (NEOG) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-05-31..
Quick ratio
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 158.20M USD | Liabilities, Current |
| Cash and equivalents | 185.50M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 146.80M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 144.30M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | (m) | $158.20M | $185.50M | (m) | $146.80M | $144.30M | (m) |
| 2026-02-28 | (m) | $150.60M | $159.90M | (m) | $137.10M | $161.70M | (m) |
| 2025-11-30 | (m) | $147.05M | $145.34M | (m) | $132.00M | $162.77M | (m) |
| 2025-08-31 | (m) | $146.21M | $138.88M | (m) | $138.46M | $193.41M | (m) |
| 2025-05-31 | $282.39M | $174.01M | $129.00M | $0.00 | $153.38M | $190.86M | 1.62× |
| 2025-02-28 | $287.77M | $141.20M | $127.70M | $0.00 | $160.07M | $205.44M | 2.04× |
| 2024-11-30 | $304.32M | $151.19M | $140.23M | $0.00 | $164.09M | $198.27M | 2.01× |
| 2024-08-31 | $288.12M | $122.69M | $120.48M | $0.00 | $167.64M | $198.60M | 2.35× |
| 2024-05-31 | $343.94M | $154.32M | $170.61M | $325.00K | $173.00M | $189.27M | 2.23× |
| 2024-02-29 | $342.04M | $157.84M | $161.44M | $7.01M | $173.59M | $182.39M | 2.17× |
| 2023-11-30 | $380.76M | $176.61M | $205.76M | $24.50M | $150.50M | $160.53M | 2.16× |
| 2023-08-31 | $376.93M | $138.13M | $178.83M | $60.42M | $137.67M | $140.69M | 2.73× |
| 2023-05-31 | $398.82M | $145.47M | $163.24M | $82.33M | $153.25M | $133.81M | 2.74× |
| 2023-02-28 | $329.61M | $107.16M | $67.13M | $116.08M | $146.39M | $143.86M | 3.08× |
| 2022-11-30 | $419.05M | $152.56M | $100.00M | $176.34M | $142.71M | $136.07M | 2.75× |
| 2022-08-31 | $440.82M | $67.00M | $107.10M | $240.61M | $93.11M | $129.04M | 6.58× |
| 2022-05-31 | $480.73M | $77.84M | $44.47M | $336.58M | $99.67M | $122.31M | 6.18× |
| 2022-02-28 | $471.42M | $65.71M | $42.88M | $335.56M | $92.98M | $113.39M | 7.17× |
| 2021-11-30 | $481.75M | $62.67M | $51.12M | $338.13M | $92.50M | $107.09M | 7.69× |
| 2021-08-31 | $488.17M | $50.76M | $71.28M | $329.60M | $87.29M | $102.11M | 9.62× |
| 2021-05-31 | $472.91M | $53.60M | $75.60M | $305.49M | $91.82M | $100.70M | 8.82× |
| 2021-02-28 | $440.59M | $45.94M | $73.48M | $279.87M | $87.24M | $99.27M | 9.59× |
| 2020-11-30 | $470.70M | $44.59M | $113.87M | $276.90M | $79.93M | $92.53M | 10.56× |
| 2020-08-31 | $445.17M | $46.44M | $60.95M | $306.54M | $77.69M | $97.57M | 9.59× |
| 2020-05-31 | $428.35M | $48.49M | $66.27M | $277.40M | $84.68M | $95.05M | 8.83× |
| 2020-02-29 | $408.62M | $39.13M | $50.77M | $277.15M | $80.69M | $89.24M | 10.44× |
| 2019-11-30 | $398.98M | $38.79M | $66.41M | $247.19M | $85.38M | $86.41M | 10.29× |
| 2019-08-31 | $370.13M | $40.43M | $56.29M | $234.73M | $79.11M | $87.68M | 9.16× |
| 2019-05-31 | $350.11M | $38.25M | $41.69M | $225.84M | $82.58M | $85.99M | 9.15× |
| 2019-02-28 | $326.69M | $34.27M | $93.58M | $153.10M | $80.01M | $84.87M | 9.53× |
| 2018-11-30 | $323.25M | $38.76M | $101.58M | $139.38M | $82.28M | $79.47M | 8.34× |
| 2018-08-31 | $304.49M | $39.22M | $97.22M | $129.19M | $78.08M | $78.77M | 7.76× |
| 2018-05-31 | $289.90M | $38.69M | $83.07M | $127.74M | $79.09M | $76.00M | 7.49× |
| 2018-02-28 | $265.36M | $37.29M | $82.07M | $110.09M | $73.21M | $77.51M | 7.12× |
| 2017-11-30 | $250.69M | $37.95M | $64.42M | $111.41M | $74.86M | $73.71M | 6.61× |
| 2017-08-31 | $226.33M | $38.32M | $58.46M | $101.53M | $66.34M | $73.41M | 5.91× |
| 2017-05-31 | $212.21M | $36.00M | $77.57M | $66.07M | $68.58M | $73.14M | 5.89× |
| 2017-02-28 | $191.95M | $34.72M | $59.88M | $64.70M | $67.37M | $75.40M | 5.53× |
| 2016-11-30 | $207.01M | $33.87M | $86.30M | $55.81M | $64.90M | $71.68M | 6.11× |
| 2016-08-31 | $188.58M | $32.64M | $76.19M | $53.04M | $59.35M | $69.84M | 5.78× |
| 2016-05-31 | $175.45M | $28.60M | $55.26M | $52.54M | $67.65M | $64.37M | 6.13× |
| 2016-02-29 | $181.31M | $27.78M | $66.86M | $58.30M | $56.16M | $65.45M | 6.53× |
| 2015-11-30 | $180.62M | $31.23M | $71.38M | $51.64M | $57.60M | $61.48M | 5.78× |
| 2015-08-31 | $170.00M | $26.90M | $42.33M | $68.63M | $59.04M | $56.11M | 6.32× |
| 2015-06-01 | (m) | (m) | $66.06M | (m) | (m) | (m) | (m) |
| 2015-05-31 | $173.37M | $25.46M | $66.06M | $48.10M | $59.21M | $51.60M | 6.81× |
| 2015-02-28 | $155.03M | $26.55M | $57.48M | $44.66M | $52.89M | $55.10M | 5.84× |
| 2014-11-30 | $146.41M | $24.12M | $49.06M | $45.25M | $52.11M | $53.50M | 6.07× |
| 2014-08-31 | $139.79M | $24.48M | $53.46M | $34.64M | $51.69M | $55.09M | 5.71× |
| 2014-05-31 | $128.40M | $24.97M | $40.67M | $35.82M | $51.90M | $51.18M | 5.14× |
| 2014-02-28 | $116.88M | $24.53M | $43.28M | $25.53M | $48.07M | $51.86M | 4.76× |
| 2013-11-30 | $124.89M | $23.29M | $43.61M | $35.48M | $45.80M | $47.33M | 5.36× |
| 2013-08-31 | $128.02M | $22.84M | $43.61M | $40.77M | $43.65M | $43.76M | 5.61× |
| 2013-05-31 | $124.11M | $17.72M | $50.03M | $35.34M | $38.74M | $38.31M | 7.00× |
| 2013-02-28 | $113.26M | $22.57M | $48.86M | $25.70M | $38.69M | $41.08M | 5.02× |
| 2012-11-30 | $108.43M | $18.32M | $41.31M | $29.53M | $37.59M | $38.38M | 5.92× |
| 2012-08-31 | $112.20M | $18.97M | $44.48M | $30.02M | $37.69M | $35.01M | 5.91× |
| 2012-05-31 | $104.30M | $19.98M | $49.05M | $19.60M | $35.65M | $34.99M | 5.22× |
| 2012-02-29 | $95.67M | $17.44M | $42.70M | $18.64M | $34.33M | $36.31M | 5.49× |
| 2011-11-30 | $87.47M | $18.41M | $36.97M | $18.63M | $31.87M | $36.42M | 4.75× |
| 2011-08-31 | $84.03M | $18.25M | $22.03M | $29.32M | $32.67M | $34.22M | 4.60× |
| 2011-05-31 | $84.72M | $17.80M | $35.84M | $20.24M | $28.63M | $31.99M | 4.76× |
| 2011-02-28 | (m) | (m) | $30.18M | (m) | (m) | (m) | (m) |
| 2010-11-30 | (m) | (m) | $27.08M | (m) | (m) | (m) | (m) |
| 2010-08-31 | (m) | (m) | $22.76M | (m) | (m) | (m) | (m) |
| 2010-05-31 | (m) | (m) | $22.81M | (m) | (m) | (m) | (m) |
| 2009-05-31 | (m) | (m) | $13.84M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |